九洲药业：富马酸伏诺拉生原料药获批准

Core Viewpoint - The approval of the chemical raw material drug Fumaric Acid Vonoprazan by the National Medical Products Administration will enhance the company's product portfolio and market competitiveness, although it is not expected to have a significant short-term impact on performance [1] Company Summary - Jiuzhou Pharmaceutical's wholly-owned subsidiary, Zhejiang Jiuzhou Pharmaceutical Technology Co., Ltd., has received the approval notice for Fumaric Acid Vonoprazan [1] - The drug is primarily used for the treatment of acid-related diseases [1] - The company has invested approximately 7.36 million yuan in research and development for this drug [1] - In 2023, the sales revenue of Fumaric Acid Vonoprazan tablets in Chinese public medical institutions exceeded 600 million yuan [1] Industry Summary - The approval of Fumaric Acid Vonoprazan is expected to enrich the company's product structure, thereby enhancing its competitiveness in the pharmaceutical industry [1]